Session

Patient journeys through metastatic castration-resistant prostate cancer: A multidisciplinary team discussion

Industry session by JANSSEN PHARMACEUTICA NV

  • Location:
    Room Madrid (Hall B2, level 0)
  • Chair:
     J.E. Gschwend, Munich (DE)
  • Aims and objectives of this session

    Discuss treatment options for patients with mCRPC

Welcome and introduction
 J.E. Gschwend, Munich (DE)
Beginning the journey – Chemotherapy-naïve metastatic castration-resistant prostate cancer (CRPC)
 
 A. Alcaraz, Barcelona (ES)
 
 K. Fizazi, Villejuif (FR)
 
 J.E. Gschwend, Munich (DE)
 
 N. Tunariu, London (GB)
 
Moderator:
 C. Hood, London (GB)
 
Interactive patient case study presentation
 
How the data support the management plan
 
Multidisciplinary team (MDT) discussion: How would we manage this patient?
Alternative starting points in newly confirmed metastatic CRPC
 
 A. Alcaraz, Barcelona (ES)
 
 K. Fizazi, Villejuif (FR)
 
 J.E. Gschwend, Munich (DE)
 
 N. Tunariu, London (GB)
 
Moderator:
 C. Hood, London (GB)
 
Interactive patient case study presentation
 
MDT discussion: How would we manage this patient?
The journey continues – Progressing metastatic CRPC
 
 A. Alcaraz, Barcelona (ES)
 
 K. Fizazi, Villejuif (FR)
 
 J.E. Gschwend, Munich (DE)
 
 N. Tunariu, London (GB)
 
Moderator:
 C. Hood, London (GB)
 
Interactive patient case study presentation
 
How the data supports the management plan
 
MDT discussion: How would we manage this patient?
Summary and close
 
 J.E. Gschwend, Munich (DE)